NCT00605397View on ClinicalTrials.gov

PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Breast Cancer
Interventions
RADIATION

PET Imaging With Cu-64 Labeled Trastuzumab

The first 8 patients enrolled will undergo two complete PET studies, up to 3-6 weeks apart, to assess for reproducibility of measures of tracer uptake into individual organs and known sites of metastatic disease.

RADIATION

PET Imaging With Cu-64 Labeled Trastuzumab

The remaining 20 patients will undergo one PET study.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00605397 - PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter